PARP inhibitors in treatment of early stage breast cancer

PARP inhibitors in treatment of early stage breast cancer

Bibliographic Details
Main Author:	A. Tutt
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000758

Similar Items

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
by: Anthony Gonçalves, et al.
Published: (2020-05-01)

PARP inhibitors are a new area in the treatment of breast cancer
by: V. P. Letyagin
Published: (2014-08-01)

An update on PARP inhibitors for the treatment of cancer
by: Benafif S, et al.
Published: (2015-02-01)

Advances in the use of PARP inhibitor therapy for breast cancer
by: Kelly E McCann, et al.
Published: (2018-08-01)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
by: Joseph A. De Soto, Xianyan Wang, Yohei Tominaga, Rui-Hong Wang, Liu Cao, Wenhui Qiao, Cuiling Li, Xiaoling Xu, Amanda P. Skoumbourdis, Sheila A. Prindiville, Craig J. Thomas, Chu-Xia Deng
Published: (2006-01-01)

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
by: Abdullah Alhusaini, et al.
Published: (2021-08-01)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
by: Ye Han, et al.
Published: (2020-11-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
by: Camille Franchet, et al.
Published: (2021-08-01)

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
by: D. S. Dolgasheva, et al.
Published: (2020-06-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
by: Lilian T. Gien, et al.
Published: (2010-01-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
by: Ali Divan, et al.
Published: (2020-04-01)

PARP inhibitor combinations in prostate cancer
by: Carmel Pezaro
Published: (2020-03-01)

PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01)

Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
by: Xiuzhi Zhu, et al.
Published: (2021-04-01)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
by: Man Yee T. Keung, et al.
Published: (2019-03-01)

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors?
by: Amanda eLovato, et al.
Published: (2012-12-01)

PARP inhibitors in female reproductive system cancers
by: I A Pokataev, et al.
Published: (2017-06-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
by: Camilla Nero, et al.
Published: (2021-03-01)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
by: Dong Wang, et al.
Published: (2017-03-01)

The role of PARP inhibitors in the treatment of gynecologic malignancies
by: Raquel E. Reinbolt, et al.
Published: (2013-10-01)

The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2
by: Hao Zuo, et al.
Published: (2020-03-01)

DNA damage sensitization of breast cancer cells with PARP10/ARTD10 inhibitor
by: Hukkanen, M. (Mikko)
Published: (2019)

HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
by: Young-Ho Lee, et al.
Published: (2015-01-01)

The role of PARP inhibitors in mutated pancreatic cancer
by: Jeffrey Chi, et al.
Published: (2021-05-01)

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
by: Nicola Curtin, et al.
Published: (2020-11-01)

Advances in using PARP inhibitors to treat cancer
by: Kummar Shivaani, et al.
Published: (2012-03-01)

Successes and challenges of PARP inhibitors in cancer therapy
by: Tiffany K Ricks, et al.
Published: (2015-10-01)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
by: Stergios Boussios, et al.
Published: (2019-05-01)

Prostate cancer and PARP inhibitors: progress and challenges
by: Diego Teyssonneau, et al.
Published: (2021-03-01)

Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01)

PARP inhibitors in gastric cancer: beacon of hope
by: Yali Wang, et al.
Published: (2021-06-01)

Therapeutic applications of PARP inhibitors in ovarian cancer
by: Hongyu Xie, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_q1q3ilafjvl891buuh3nh4sojk